Isolate no.
|
Ceftriaxone MICs (mg/L)
|
Antimicrobial characteristics
|
NG-MAST
|
PBP2 allele
|
Polymorphisms in:
|
---|
porB
|
tbpB
|
STs
|
MtrR
|
PorB1b
|
PBP1
|
PilQ
|
---|
NJ-1
|
0.25
|
CMRNG, CipR#
|
5658
|
111
|
9530*
|
XVIII
|
−57A del, A39T
|
G120K, A121D
|
L421P
|
wt
|
NJ-2
|
0.25
|
CMRNG, CipR
|
5175
|
328
|
8737
|
XVIII
|
−57A del, A39T
|
G120K, A121D
|
L421P
|
wt
|
NJ-3
|
0.125
|
PPNG, CipR
|
5659
|
107
|
9531*
|
XVIII
|
−57A del
|
G120K, A121G
|
L421P
|
wt
|
NJ-4
|
0.125
|
PP/TRNG, CipR
|
1053
|
186
|
3289
|
XVIII
|
−57A del
|
G120K, A121D
|
L421P
|
wt
|
NJ-5
|
0.125
|
PPNG, CipR
|
1854
|
33
|
9532*
|
XLI**
|
−57A del
|
G120N, A121D
|
L421P
|
wt
|
NJ-6
|
0.125
|
PP/TRNG, CipR
|
543
|
294
|
9533*
|
XVIII
|
A39T
|
G120K, A121G
|
L421P
|
wt
|
NJ-7
|
0.125
|
CMRNG, CipR
|
5660
|
186
|
9534*
|
XVIII
|
−57A del
|
G120K, A121G
|
L421P
|
wt
|
NJ-8
|
0.125
|
CMRNG, CipR
|
505
|
135
|
2186
|
XVIII
|
−57A del
|
G120K, A121D
|
L421P
|
wt
|
NJ-9
|
0.125
|
CMRNG, CipR
|
1285
|
4
|
9535*
|
XIII
|
−57A del, G45D
|
G120K, A121D
|
L421P
|
wt
|
NJ-10
|
0.125
|
TRNG, CipR
|
4
|
831
|
3746
|
XIII
|
−57A del
|
G120K, A121D
|
L421P
|
wt
|
NJ-11
|
0.125
|
CMRNG, CipR
|
3530
|
4
|
9536*
|
XVIII
|
−57A del
|
G120K, A121G
|
L421P
|
wt
|
NJ-12
|
0.125
|
CMRNG, CipR
|
1198
|
156
|
2461
|
XVIII
|
−57A del, A39T
|
G120K, A121G
|
L421P
|
wt
|
NJ-13
|
0.125
|
CMRNG, CipR
|
5661
|
4
|
5061
|
XVIII
|
−57A del, G45D
|
G120K, A121N
|
L421P
|
wt
|
NJ-14
|
0.125
|
CMRNG, CipR
|
2978
|
1058
|
9537*
|
XII
|
−57A del
|
G120K, A121D
|
L421P
|
wt
|
NJ-15
|
0.125
|
TRNG, CipR
|
543
|
438
|
9538*
|
XVIII
|
−57A del
|
G120K, A121G
|
L421P
|
wt
|
- wt, wild type.
- *New NG-MAST STs detected in this study.
- **A new PBP2 allele previously not identified was named XLI according to previously used Nomenclature.
-
#isolates exhibiting resistance to ciprofloxacin (MIC ≥ 1 mg/L).